Showing 40,301 - 40,320 results of 145,922 for search '(( i we decrease ) OR ( 5 ((point decrease) OR (((a decrease) OR (mean decrease)))) ))', query time: 2.10s Refine Results
  1. 40301

    CoREST1 Promotes Tumor Formation and Tumor Stroma Interactions in a Mouse Model of Breast Cancer by Sohini Mazumdar (707540)

    Published 2015
    “…Notably, CoREST1-depleted cells gave rise to tumors with a marked decrease in angiogenesis. …”
  2. 40302

    LncRNA RUNX1-IT1 affects the differentiation of Th1 cells by regulating NrCAM transcription in Graves’ disease by Feng-Jiao Huang (3413105)

    Published 2022
    “…We performed RNA pull down, RIP, and ChIP experiments to verify the correlation between p53 and RUNX1-IT1, p53 and NrCAM. …”
  3. 40303

    S1 Data - by Yoshinao Katsu (1276812)

    Published 2023
    “…To determine if, similar to lamprey CR1, the presence of this insert in elephant shark MR and GR decreases transcriptional activation by corticosteroids, we inserted these four CR1-specific residues into the DBD of elephant shark MR and GR. …”
  4. 40304
  5. 40305
  6. 40306
  7. 40307
  8. 40308
  9. 40309

    DataSheet1_Assessment of Strategies for Safe Drug Discontinuation and Transition of Denosumab Treatment in PMO—Insights From a Mechanistic PK/PD Model of Bone Turnover.pdf by Javier Martínez-Reina (849042)

    Published 2022
    “…This new model also showed that Dmab withdrawal leads to a rapid increase of damage in the bone matrix, which in turn decreases the local safety factor for fatigue failure. …”
  10. 40310

    DataSheet1_Assessment of Strategies for Safe Drug Discontinuation and Transition of Denosumab Treatment in PMO—Insights From a Mechanistic PK/PD Model of Bone Turnover.pdf by Javier Martínez-Reina (849042)

    Published 2022
    “…This new model also showed that Dmab withdrawal leads to a rapid increase of damage in the bone matrix, which in turn decreases the local safety factor for fatigue failure. …”
  11. 40311

    DataSheet1_Assessment of Strategies for Safe Drug Discontinuation and Transition of Denosumab Treatment in PMO—Insights From a Mechanistic PK/PD Model of Bone Turnover.pdf by Javier Martínez-Reina (849042)

    Published 2022
    “…This new model also showed that Dmab withdrawal leads to a rapid increase of damage in the bone matrix, which in turn decreases the local safety factor for fatigue failure. …”
  12. 40312

    <i>P</i> values for several categories of land usage. by Yi Bai (450166)

    Published 2024
    “…<div><p>Soil erosion is one of the main issues that endangers global ecosystems. …”
  13. 40313
  14. 40314
  15. 40315
  16. 40316

    Influences of Surface Substitutional Ti Atom on Hydrogen Adsorption, Dissociation, and Diffusion Behaviors on the α‑U(001) Surface by Peng Shi (132534)

    Published 2014
    “…However, the diffusion of the dissociated hydrogen atoms is dramatically changed after introduction of a surface substitutional Ti atom. The into-bulk penetration of a hydrogen atom through a defect-free surface is endothermic and needs to overcome an energy barrier of 0.8–0.9 eV. …”
  17. 40317

    Supplementary Material for: Plasma Mucin-1 (CA15-3) Levels in Autosomal Dominant Tubulointerstitial Kidney Disease due to <b><i>MUC1</i></b> Mutations by Vylet’al P. (10932213)

    Published 2021
    “…We hypothesized that ADTKD-<i>MUC1</i> patients, who have only 1 secretory-competent wild-type <i>MUC1</i> allele, should exhibit decreased plasma mucin-1 (MUC1) levels. …”
  18. 40318

    Myostain is involved in ginsenoside Rb1-mediated anti-obesity by Hong-Shi Li (12698363)

    Published 2023
    “…MSTN was downregulated in differentiated C2C12 cells, 3T3-L1 cells and adipose tissues upon Rb1 treatment. FNDC5 was increased after Rb1 treatment. However, MSTN overexpression attenuated Rb1-mediated decrease accumulation of lipid droplets in differentiated 3T3-L1 adipocytes.…”
  19. 40319
  20. 40320

    Discovery of <i>N</i>‑(1,3,4-Thiadiazol-2-yl)amide Derivatives as Uncompetitive Inhibitors of 6‑Phosphogluconate Dehydrogenase by Rong Zhang (44942)

    Published 2025
    “…However, potent 6PGD inhibitors remain limited. Herein, we report a series of <i>N</i>-(1,3,4-thiadiazol-2-yl)amide derivatives as 6PGD inhibitors, via <i>in vitro</i> enzymatic assay-based high-throughput screening and structure–activity relationship analysis. …”